Parabolic Drugs has reported results for first quarter ended June 30, 2012.
The company has reported a fall of 35.70% in its net profit at Rs 9.76 crore for the quarter under review as compared to a net profit of Rs 15.18 crore for the same quarter in the previous year. However, the total income from operation of the company has increased by 62.72% at Rs 307.32 crore for Q1FY13 as compared Rs 188.87 crore for the corresponding quarter previous year.
Parabolic Drugs has recommend dividend of Rs 0.25 per share on fully paid equity shares of the company for the year 2011-2012.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1696.65 |
| Dr. Reddys Lab | 1218.30 |
| Cipla | 1226.65 |
| Zydus Lifesciences | 936.00 |
| Lupin | 2339.20 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: